Crescent Biopharma (CBIO) EBIAT (2016 - 2025)
Crescent Biopharma (CBIO) has disclosed EBIAT for 11 consecutive years, with -$107.1 million as the latest value for Q4 2025.
- On a quarterly basis, EBIAT changed N/A to -$107.1 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$153.9 million, a N/A change, with the full-year FY2025 number at -$153.9 million, down 306.29% from a year prior.
- EBIAT was -$107.1 million for Q4 2025 at Crescent Biopharma, down from -$21.8 million in the prior quarter.
- In the past five years, EBIAT ranged from a high of -$8.3 million in Q2 2023 to a low of -$107.1 million in Q4 2025.
- A 5-year average of -$17.9 million and a median of -$12.0 million in 2022 define the central range for EBIAT.
- Peak YoY movement for EBIAT: soared 50.82% in 2022, then tumbled 115.84% in 2025.
- Crescent Biopharma's EBIAT stood at -$17.4 million in 2021, then surged by 41.2% to -$10.2 million in 2022, then grew by 11.38% to -$9.1 million in 2023, then fell by 8.21% to -$9.8 million in 2024, then tumbled by 990.53% to -$107.1 million in 2025.
- Per Business Quant, the three most recent readings for CBIO's EBIAT are -$107.1 million (Q4 2025), -$21.8 million (Q2 2025), and -$15.1 million (Q1 2025).